Drug Profile
Trimebutine 3-thiocarbamoylbenzenesulfonate
Alternative Names: GIC-1001; TB-905-02Latest Information Update: 24 Oct 2021
Price :
$50
*
At a glance
- Originator Antibe Therapeutics
- Developer gIcare Pharma
- Class Antispasmodics; Benzenesulfonates; Benzoic acids; Irritable bowel syndrome therapies; Opioid analgesics; Organic sulfur compounds; Phenylbutyrates
- Mechanism of Action Muscarinic receptor antagonists; Neurotransmitter modulators; Opioid kappa receptor agonists; Opioid mu receptor agonists; Oxygen radical scavengers
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Irritable bowel syndrome; Procedural pain
Most Recent Events
- 17 Feb 2016 No recent reports on development identified - Phase-II for Procedural pain in USA and Canada (PO)
- 17 Feb 2016 No recent reports on development identified - Preclinical for Irritable bowel syndrome in Canada (PO)
- 01 Dec 2014 gIcare Pharma completes a phase Ib trial in healthy volunteers in Canada (NCT02276768)